ABOUT US

3DBiopsy, Inc. is a medical device company that is developing a comprehensive System ultimately intended to aid in the diagnosis and treatment planning of prostate cancer—the most commonly diagnosed significant male cancer and second leading cause of cancer deaths. Created by prostate cancer specialists, the 3DBiopsy System is expected to achieve improvements in biopsy accuracy which may reduce the need for radical surgery or full radiation and lower costs for the healthcare industry.

MANAGEMENT

Dr. Nelson Stone

Founder and CEO/President

  • Dr. Stone is Professor of Urology and Radiation Oncology at the Icahn School of Medicine at Mt Sinai, NYC and has authored over 400 articles, abstracts and book chapters and recently  co-authored a new book on localized prostate cancer entitled “The Prostate Cancer Dilemma:  To Treat or Observe, Impact of Genetic Markers, Mapping and mpMRI.”
  • In 1995, Dr. Stone created the 3D Brachytherapy System, PROSEED which was sold to CR Bard in 1998 for $84M.
  • In 2005, Dr. Stone started Prologics, a prostate cancer radiation ablation therapy company that was successfully sold to Integrated Oncology Network in 2011 for a $10 million valuation.

Brad J. Buscher

Chairman of the Board

  • Mr. Buscher is a merchant banker and through his business has led the financing of the Company to date.
  • He is responsible for the Company’s current product development, product engineering, FDA clearance, IP protection strategy and establishing the Company’s reimbursement strategy.
  • Mr. Buscher has extensive experience with start-up investments in healthcare, medical diagnostics, inorganic chemistry and real estate and has been the Chairman of commercial banks, insurance brokerages, real estate development entities, leasing companies and has extensive experience in the formation and development of early stage enterprises.

Dr. E. David Crawford

Co-Founder and Chief Medical Advisor

  • Dr. Crawford is an internationally renowned urologist, Endowed Professor of Surgery, Urology and Radiation Oncology.
  • He is Head of the Section of Urologic Oncology at the CU Denver Health Sciences Center and School of Medicine.

Dr. Marshall Lucia

Co-Founder, leads the development of the 3D pathology software

  • Dr. Lucia is Professor of Pathology and Vice Chair of Anatomic Pathology at the CU Denver Health Sciences Center and School of Medicine.
  • He has over 20 years of experience in translational biopsy research and 12 years of experience in bio-repository.

Todd Anderson

Chief Financial Officer

  • Mr. Anderson has worked with Mr. Buscher for almost 20 years setting up and growing early-stage companies.
  • He brings his extensive background in setting up systems and controls for start-up entities to the initial phase of financing and operational functions of 3DBiopsy.

Jim Rosa

VP, Regulatory and Quality Assurance

  • Mr. Rosa will lead the Company’s regulatory compliance and quality systems initiatives.
  • He has 35 years of experience in advanced R&D, and Quality Assurance and Regulatory Affairs within regulated industries, primarily medical device, within the U.S. and Europe as well as support to Asia.

*Investigational device. Not available for sale in the United States.

Investor Inquiries Welcome.

.

Call us at 1-800-290-6186, or email us

Brad J. Buscher
Chairman of the Board
Cell: 612-859-2551
bbuscher@3dbiopsy.com

Nelson N. Stone, MD 
President, Chief Executive Officer and Founder
Cell: 845-323-1727
nstone@3dbiopsy.com

James R. Rosa 
Vice President, Regulatory and Quality Assurance
Cell: 303-704-3374
jrosa@3dbiopsy.com

Todd J. Anderson 
Chief Financial Officer
Cell: 612-839-2457
tanderson@3dbiopsy.com

E. David Crawford, MD 
Chief Medical Advisor and Founder
Cell: 303-315-5937
dcrawford@3dbiopsy.com